CA2417874C - Utilisation des inhibiteurs ox-2 pour le traitement du cancer - Google Patents

Utilisation des inhibiteurs ox-2 pour le traitement du cancer Download PDF

Info

Publication number
CA2417874C
CA2417874C CA2417874A CA2417874A CA2417874C CA 2417874 C CA2417874 C CA 2417874C CA 2417874 A CA2417874 A CA 2417874A CA 2417874 A CA2417874 A CA 2417874A CA 2417874 C CA2417874 C CA 2417874C
Authority
CA
Canada
Prior art keywords
cells
tumor
mice
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2417874A
Other languages
English (en)
Other versions
CA2417874A1 (fr
Inventor
Reginald M. Gorczynski
David A. Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trillium Therapeutics ULC
Original Assignee
Trillium Therapeutics ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trillium Therapeutics ULC filed Critical Trillium Therapeutics ULC
Publication of CA2417874A1 publication Critical patent/CA2417874A1/fr
Application granted granted Critical
Publication of CA2417874C publication Critical patent/CA2417874C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés et des compositions permettant de réguler la croissance des tumeurs. Afin de réduire la croissance tumorale, on administre des agents qui inhibent OX-2. Ces procédés sont utiles dans le traitement du cancer. Afin d'accroître la croissance tumorale, on administre une protéine OX-2 ou un acide nucléique codant une protéine OX-2. Ces procédés sont utiles dans la recherche sur le cancer et/ou la métastase tumorale.
CA2417874A 2000-08-03 2001-07-30 Utilisation des inhibiteurs ox-2 pour le traitement du cancer Expired - Fee Related CA2417874C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22272500P 2000-08-03 2000-08-03
US60/222,725 2000-08-03
PCT/CA2001/001111 WO2002011762A2 (fr) 2000-08-03 2001-07-30 Procedes et compositions utiles pour moduler la croissance des tumeurs

Publications (2)

Publication Number Publication Date
CA2417874A1 CA2417874A1 (fr) 2002-02-14
CA2417874C true CA2417874C (fr) 2012-10-02

Family

ID=22833418

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2417874A Expired - Fee Related CA2417874C (fr) 2000-08-03 2001-07-30 Utilisation des inhibiteurs ox-2 pour le traitement du cancer

Country Status (3)

Country Link
AU (1) AU2001278338A1 (fr)
CA (1) CA2417874C (fr)
WO (1) WO2002011762A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE406385T1 (de) 2000-11-22 2008-09-15 Trillium Therapeutics Inc Verkürztes cd200
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
AU2004217434B2 (en) * 2000-12-08 2010-08-26 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
CA2436595C (fr) 2000-12-08 2011-11-08 Alexion Pharmaceuticals, Inc. Lignee cellulaire de la leucemie lymphoide chronique et son utilisation pour la production d'un anticorps
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
NZ553470A (en) * 2002-03-15 2008-10-31 Schering Corp Methods of modulating CD200 receptors
AU2003299823A1 (en) * 2002-12-27 2004-07-29 Schering Corporation Methods of inducing and maintaining immune tolerance
AU2012211347B9 (en) * 2004-07-20 2015-06-18 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
SG10201400426XA (en) 2006-01-12 2014-07-30 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
AU2008279618B2 (en) 2007-07-25 2014-05-22 Alexion Pharmaceuticals, Inc. Methods and compositions for treating autoimmune disease
SG182408A1 (en) 2010-01-11 2012-08-30 Alexion Pharma Inc Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
KR20130036192A (ko) 2010-02-11 2013-04-11 알렉시온 파마슈티칼스, 인코포레이티드 항-ｃｄ200 항체들을 이용한 치료 및 진단 방법
EP2723380B1 (fr) 2011-06-24 2019-08-21 Stephen D. Gillies Protéines hybrides d'immunoglobuline à chaîne légère et leurs procédés d'utilisation
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
WO2019126133A1 (fr) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Formulations liquides d'anticorps anti-cd200
WO2019126536A1 (fr) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Anticorps humanisés anti-cd200 et leurs utilisations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1032662B1 (fr) * 1997-11-07 2006-03-08 Trillium Therapeutics Inc. Procedes et compositions pour immunomodulation

Also Published As

Publication number Publication date
CA2417874A1 (fr) 2002-02-14
AU2001278338A1 (en) 2002-02-18
WO2002011762A2 (fr) 2002-02-14
WO2002011762A3 (fr) 2003-03-13

Similar Documents

Publication Publication Date Title
CA2417874C (fr) Utilisation des inhibiteurs ox-2 pour le traitement du cancer
US8187598B2 (en) Methods of treating cancer by administering antibodies to CD200
US7902151B2 (en) Methods and compositions for modulating immunity
US7553811B2 (en) Methods and compositions for modulating immunity
Gorczynski et al. Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice
US20120269806A1 (en) Methods of inducing tolerance
CA2448668A1 (fr) Modulation des recepteurs de cd200
WO2024041761A1 (fr) Combinaison de récepteurs de lymphocytes t spécifiques de ny-eso-1 et de récepteurs chimériques de costimulation
AU2020307688B2 (en) Combination cancer immunotherapy
Takayama et al. Antigen-specific directional target cell lysis by perforin-negative T lymphocyte clones
Chen et al. Administration of a CD31-derived peptide delays the onset and significantly increases survival from lethal graft-versus-host disease
RU2803148C2 (ru) Противоопухолевое средство и способ его оценки
US20220347282A1 (en) Anti-tumor dna vaccine with pd-1 and lag-3 pathway blockade
US20100297146A1 (en) Immune system programming through b7-dc
CN114786701A (zh) 用于治疗癌症的包括包含il-2蛋白和cd80蛋白的融合蛋白和免疫检查点抑制剂的药物组合物
HK40074839A (en) Pharmaceutical composition for treatment of cancer, comprising immune checkpoint inhibitor and fusion protein including il-2 protein and cd80 protein
HK40024980A (en) Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies
HK1030625B (en) Methods and compositions for immunomodulation

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140730